









Mercados
/
Ações
/
nasdaq-abbv
/

AbbVie Inc

ABBV

221.590USD

+0.780+0.35%

Horário de mercado （ET）Cotações atrasadas em 15 min

391.43BValor de mercado

105.14P/L TTM



AbbVie Inc

221.590

+0.780+0.35%

Visão Geral Empresa Serviços Financeiros Análises

AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It researches and develops, manufactures, commercializes and sells medicines and therapies. Its product portfolio includes immunology, oncology, aesthetics, neuroscience, eye care and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia and Diffuse large B-cell lymphoma. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers and others. Its NX-13 for the treatment of ulcerative colitis and Crohn's disease. Its CEL383 for the treatment of inflammatory bowel disease. Its ALIA-1758 for the treatment of patients with Alzheimer's disease.

Informações da empresa

Código da empresaABBV

Nome da EmpresaAbbVie Inc

Data de listagemJan 02, 2013

CEOMr. Robert A. Michael, CPA

Número de funcionários55000

Tipo de títulosOrdinary Share

Fim do ano fiscalJan 02

Endereço1 N Waukegan Rd

CidadeNORTH CHICAGO

Bolsa de valoresNYSE Consolidated

PaísUnited States of America

Código postal60064

Telefone18479327900

Sitehttps://www.abbvie.com/

Código da empresaABBV

Data de listagemJan 02, 2013

CEOMr. Robert A. Michael, CPA

Executivos da empresa

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Mr. Frederick H. (Rick) Waddell

Independent Director

28.96K

+4.33%

Ms. Melody B. Meyer

Independent Director

16.50K

+7.87%

Mr. Timothy J. Richmond

Chief Human Resources Officer, Executive Vice President

6.13K

-77.61%

Ms. Jennifer L. Davis

Independent Director

2.52K

+91.00%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Azita Saleki-Gerhardt, Ph.D.

Executive Vice President, Chief Operations Officer

183.77K

Mr. Thomas C. (Tom) Freyman, CPA

Independent Director

134.63K

+0.90%

Mr. Edward J. (Ed) Rapp

Independent Director

42.95K

+2.88%

Dr. Roopal Thakkar, M.D.

Executive Vice President - Research & Development, Chief Scientific Officer

42.28K

+16.15%

Ms. Roxanne S. Austin, CPA

Lead Independent Director

38.46K

+3.23%

Dr. Robert J. Alpern, M.D.

Independent Director

35.65K

+3.49%

Detalhamento da receita

Moeda: USDAtualizado em: dom, 6 de jul

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Immunology-SKYRIZI

3.42B

25.21%

Immunology-RINVOQ

1.72B

12.64%

Immunology-HUMIRA

1.12B

8.25%

Hematologic Oncology-IMBRUVICA

947.00M

6.97%

Neuroscience-Botox Therapeutic

866.00M

6.37%

Outro

5.51B

40.56%

Por RegiãoUSD

Nome

Receita

Proporção

United States

9.39B

69.13%

International

3.20B

23.56%

All other countries

747.00M

5.50%

Collaboration revenue

245.00M

1.80%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Immunology-SKYRIZI

3.42B

25.21%

Immunology-RINVOQ

1.72B

12.64%

Immunology-HUMIRA

1.12B

8.25%

Hematologic Oncology-IMBRUVICA

947.00M

6.97%

Neuroscience-Botox Therapeutic

866.00M

6.37%

Outro

5.51B

40.56%

Distribuição de ações

Atualizado em: dom, 17 de ago

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

9.99%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Global Advisors (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.12%

Outro

75.93%

Investidores

Proporção

The Vanguard Group, Inc.

9.99%

BlackRock Institutional Trust Company, N.A.

5.21%

State Street Global Advisors (US)

4.53%

Geode Capital Management, L.L.C.

2.22%

JP Morgan Asset Management

2.12%

Outro

75.93%

Tipos de investidores

Investidores

Proporção

Investment Advisor

43.57%

Investment Advisor/Hedge Fund

19.92%

Research Firm

3.07%

Bank and Trust

2.29%

Pension Fund

2.19%

Sovereign Wealth Fund

1.40%

Hedge Fund

1.28%

Insurance Company

0.68%

Family Office

0.20%

Outro

25.39%

Participação acionária institucional

Atualizado em: ter, 1 de jul

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q2

5271

1.32B

74.93%

+10.38M

2025Q1

5332

1.32B

74.90%

+11.71M

2024Q4

5219

1.31B

74.47%

+8.91M

2024Q3

4974

1.30B

73.54%

-7.44M

2024Q2

4916

1.30B

73.53%

+2.27M

2024Q1

4930

1.29B

72.58%

-1.47M

2023Q4

4882

1.28B

72.31%

-1.48M

2023Q3

4694

1.27B

71.87%

-12.06M

2023Q2

4688

1.26B

71.51%

-30.42M

2023Q1

4658

1.27B

71.97%

-18.58M

Ver Mais

Atividade dos acionistas

Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

177.27M

10.04%

+4.12M

+2.38%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

91.03M

5.15%

+950.86K

+1.06%

Mar 31, 2025

State Street Global Advisors (US)

79.96M

4.53%

+341.48K

+0.43%

Mar 31, 2025

Geode Capital Management, L.L.C.

38.25M

2.17%

+1.11M

+2.98%

Mar 31, 2025

JP Morgan Asset Management

35.61M

2.02%

+1.70M

+5.02%

Mar 31, 2025

Charles Schwab Investment Management, Inc.

25.27M

1.43%

-2.17M

-7.91%

Mar 31, 2025

Capital Research Global Investors

33.51M

1.9%

-475.69K

-1.40%

Mar 31, 2025

Morgan Stanley Smith Barney LLC

23.25M

1.32%

+571.37K

+2.52%

Mar 31, 2025

Norges Bank Investment Management (NBIM)

25.10M

1.42%

+2.62M

+11.64%

Dec 31, 2024

Fidelity Management & Research Company LLC

21.43M

1.21%

+4.44M

+26.15%

Mar 31, 2025

Ver Mais

ETFs Relacionados

Atualizado em: sáb, 6 de set

Nome

Proporção

Direxion Daily Healthcare Bull 3X Shares

5.47%

Bahl & Gaynor Dividend ETF

2.85%

Capital Group Conservative Equity ETF

1.81%

PIMCO RAFI ESG US ETF

1.67%

Franklin US Large Cap Multifactor Index ETF (US)

1.63%

ALPS O'Shares US Quality Dividend ETF

1.1%

Stance Sustainable Beta ETF

1.04%

iShares Climate Conscious & Transtn MSCI USA ETF

0.91%

Franklin US Equity Index ETF

0.69%

Columbia Research Enhanced Core ETF

0.69%

Ver Mais

Direxion Daily Healthcare Bull 3X Shares

Proporção5.47%

Bahl & Gaynor Dividend ETF

Proporção2.85%

Capital Group Conservative Equity ETF

Proporção1.81%

PIMCO RAFI ESG US ETF

Proporção1.67%

Franklin US Large Cap Multifactor Index ETF (US)

Proporção1.63%

ALPS O'Shares US Quality Dividend ETF

Proporção1.1%

Stance Sustainable Beta ETF

Proporção1.04%

iShares Climate Conscious & Transtn MSCI USA ETF

Proporção0.91%

Franklin US Equity Index ETF

Proporção0.69%

Columbia Research Enhanced Core ETF

Proporção0.69%

Dividendo

Um total de 48.58B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Oct 30, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.64 paid on Feb 14, 2025 going ex on Jan 15, 2025

Jan 15, 2025

Feb 14, 2025

Jan 15, 2025

Sep 06, 2024

ABBV.NB Final Cash Dividend of gross USD 1.55 paid on Nov 15, 2024 going ex on Oct 15, 2024 with reinvestment option

Oct 15, 2024

Nov 15, 2024

Oct 15, 2024

Jun 21, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option

Jul 15, 2024

Aug 15, 2024

Jul 15, 2024

Feb 15, 2024

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on May 15, 2024 going ex on Apr 12, 2024 with reinvestment option

Apr 15, 2024

May 15, 2024

Apr 12, 2024

Oct 27, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.55 paid on Feb 15, 2024 going ex on Jan 12, 2024 with reinvestment option

Jan 16, 2024

Feb 15, 2024

Jan 12, 2024

Sep 11, 2023

ABBV.NB Final Cash Dividend of gross USD 1.48 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option

Oct 13, 2023

Nov 15, 2023

Oct 12, 2023

Jun 22, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option

Jul 14, 2023

Aug 15, 2023

Jul 13, 2023

Feb 16, 2023

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option

Apr 14, 2023

May 15, 2023

Apr 13, 2023

Oct 28, 2022

ABBV.NB Interim Cash Dividend of gross USD 1.48 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option

Jan 13, 2023

Feb 15, 2023

Jan 12, 2023

Sep 09, 2022

ABBV.NB Final Cash Dividend of gross USD 1.41 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option

Oct 14, 2022

Nov 15, 2022

Oct 13, 2022

Ver Mais

Desdobramento de ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

KeyAI

